The initial success of Viagra undeniably revolutionized the pharmaceutical landscape, but investing in companies strongly reliant on unbranded versions presents a complex picture. Despite early earnings were impressive, the expiration of patents and the appearance of cheaper alternatives have diminished market share. Therefore, a thorough analysis